
Chronic migraine is a disabling pain disorder with a marked female predominance and increased prevalence during midlife. However, the biological mechanisms underlying these sex- and age-related differences remain poorly understood. Emerging evidence implicates neuroimmune signaling in migraine pathophysiology, but how immune responses vary by sex and age has not been systematically examined in preclinical models. In this study, young adult (8–10 weeks) and middle-aged (40–42 weeks) male and female C57BL/6 J mice received intraperitoneal nitroglycerin (10 mg/kg) or saline. Mechanical allodynia, thermal hyperalgesia, cold sensitivity, and locomotion, as well as plasma and cortex cytokine profiles, were assessed.Nitroglycerin produced hind paw mechanical allodynia across groups, except middle-aged males, with minimal effects on thermal sensitivity. Notably, immune responses exhibited sex- and age-dependent divergence. Female mice demonstrated distinct cytokine alterations, including increased plasma IL-1β in young adults and reduced cortical IL-17A (CTLA-8) in middle-aged animals. In young adult female mice, cortical IL-2 expression was selectively reduced and positively correlated with hind paw mechanical withdrawal thresholds, further supporting a sex-specific neuroimmune signature.These findings indicate that migraine-like pain is associated with sex- and age-dependent immune responses. Moreover, our results show that age is a biological variable in preclinical migraine research and suggest that the neuroimmune mechanisms underlying chronic migraine development may differ across the lifespan.
Lysosomal trafficking and homeostasis are biological functions that are pivotal for DRG neurons, given their metabolic demands and extremely long axons. Previous studies indicate that lysosomal signaling is altered in a mouse model of chemotherapy-induced peripheral neuropathy (CIPN) and that blocking mitogen activated protein kinase-associated kinase (MNK1/2) signaling can alleviate pain behaviors in CIPN. Here, we investigated lysosome dynamics and lysosome-associated signaling in a mouse model of CIPN induced by paclitaxel (PTX), a chemotherapeutic agent used for various types of cancer. Using spinning disk super-resolution microscope (SPINSR), we demonstrate that PTX treatment in vivo causes reduced lysosome motility observed in vitro. PTX likewise drives the accumulation of Sequestosome 1 (SQSTM1), also known as P62, in cultured mouse DRG neurons, indicating lysosomal dysfunction in DRG neurons. The transcription factor EB (TFEB), a master regulator of lysosomal biogenesis, was also upregulated in the nucleus of cultured mouse DRG neurons treated with PTX. In line with this, increased lysosomal-associated membrane protein 1 (LAMP1) expression was observed in PTX-treated mice. Given that our previous work demonstrated PTX treatment increases MNK1/2-eIF4E signaling in DRG neurons, we examined whether MNK1/2 inhibition could rescue lysosomal dysfunction. Treatment with Tomivosertib (eFT508), a potent MNK1/2 inhibitor, restored P62 levels in DRG neurons of PTX-treated mice and reduced TFEB in DRG treated in vitro. To establish translation relevance, we further show that PTX elevates phosphorylated eiF4E (p-eIF4E) in human DRG neurons, and concurrent eFT508 administration attenuates this effect. Collectively, these findings indicated that PTX disrupts lysosome trafficking and biogenesis, and that MNK inhibition with eFT508 restores lysosomal signaling and can serve as a neuroprotective strategy for CIPN.
Chronic postsurgical pain (CPSP) affects 15–20% of patients undergoing major surgery, with limited therapeutic options available for its prevention and treatment. CPSP is heterogeneous, with multiple central and peripheral mechanisms implied in contributing to its development. Current animal models have not been successful in capturing the heterogeneity subsumed within CPSP, resulting in limited translational success of interventions that show efficacy in rodents. The IMPETUS (Integrated Mechanisms, Phenotypes, and Translational Underpinnings of chronic pain after Surgery) project aims to characterize and quantify the clinical and biological heterogeneity of CPSP and investigate the mechanisms underlying these heterogeneous states. We will use an integrated approach that captures peripheral and central contributors to CPSP heterogeneity, both in humans after major abdominal surgery, and in a mouse laparotomy model. The human cross-sectional cohort will consist of about 220 patients who developed CPSP after major abdominal surgery, and about 100 control patients who underwent similar surgeries in the same timeframe but did not develop CPSP. In both species, we will investigate and compare peripheral neural and immune mechanisms, as well as central cognitive, affective, and behavioral measures associated with CPSP. We will use various modeling techniques, including machine learning approaches, to identify discrete CPSP phenotypes in humans. The features most strongly associated with each phenotype will then be compared with corresponding outcome measures in mice, allowing back-translation to model clinically relevant correlates of CPSP in mice. Establishing mouse models with measures that represent clinically meaningful CPSP phenotypes can help identify pathways and interventions that can be forward-translated and tested in relevant human subgroups. We expect this suggested feedback-loop translational research (FLTR) paradigm to lead to personalized prevention and treatment approaches to mitigate CPSP.
Background and aims Bortezomib as a first-line treatment for multiple myeloma leads to bortezomib-induced peripheral neuropathy (BIPN), a dose-limiting side effect. We aimed to characterize the temporal course of BIPN and to investigate molecular and cellular changes associated with its development and resolution. Methods Male Wistar rats received intraperitoneal injections of either 5% dimethyl sulfoxide (DMSO, vehicle) or bortezomib (0.2 mg/kg) on days 1, 4, 8, and 11 and hypersensitivity was monitored. Sciatic nerves were assessed for morphological changes and levels of interleukin (IL)-6 and IL-1β, and skin was examined for innervation density. Serum was analysed for neurofilament light (NfL) and BTZ concentrations. Dorsal root ganglia were examined for neuronal and satellite glial cell (SGC) activation. Results Bortezomib induced mild mechanical allodynia that peaked at day 12 and resolved by day 25, whereas DMSO caused transient hypersensitivity. No reduction of skin innervation was detected in either group. Serum bortezomib was detectable within 30 min post-injection until day 25. The sciatic nerves showed moderate macrophage presence, but no elevated levels of IL-6 and IL-1β. Dorsal root ganglion calcitonin gene-related peptide immunoreactive neurons increased on day 12 in the bortezomib group. Serum NfL remained unchanged across groups. SGC activation was present in both bortezomib and DMSO-treated rats and persisted at day 25. Interpretation This low-dose, reversible BIPN model entailed transient hypersensitivity and neuronal activation without axonal loss. Persistent activation of SGC indicated a glial response despite the absence of detectable structural neuronal damage. DMSO effects should be considered when interpreting preclinical pain models.
Although cognitive dysfunction associated with chronic pain has attracted growing attention, few studies have specifically focused on cognitive dysfunction induced by chronic post-thoracotomy pain (CPTP). Neuroinflammation is well recognized as a critical driver of chronic pain-related cognitive dysfunction, and vitamin D receptor (VDR) activation exerts potent anti-neuroinflammatory effects. However, whether the selective VDR agonist paricalcitol can ameliorate CPTP-induced cognitive dysfunction remains unclear. Here, we investigated the therapeutic effects of paricalcitol on CPTP-associated cognitive dysfunction and explored the underlying mechanisms. Rats were assigned to receive thoracotomy (to establish the CPTP model) or sham surgery as control. Paricalcitol or normal saline was intraperitoneally administered once daily for 5 days before surgery and once every other day for 28 days postoperatively. Mechanical pain threshold was evaluated using von Frey filaments. Locomotor activity, novel object recognition, and Barnes maze tests were performed to assess general locomotion and cognitive function. Hippocampal tissues were collected to detect key markers of neuroplasticity (doublecortin, NR1, NR2A, NR2B, GluA1, and GluA2) and neuroinflammation (IL-1β, TNF-α, and Iba1). Cecal contents were analyzed for gut microbiota composition, and colonic VDR protein expression was further quantified. We found that CPTP successfully induced persistent mechanical hypersensitivity and severe cognitive dysfunction, accompanied by excessive neuroinflammation, impaired neurogenesis, reduced NR2B expression, significant gut microbiota dysbiosis, and decreased colonic VDR protein levels. Notably, paricalcitol treatment substantially alleviated mechanical pain hypersensitivity and rescued CPTP-associated cognitive dysfunction. These beneficial effects were accompanied by improved hippocampal neuroplasticity, suppressed neuroinflammation, restored gut microbial homeostasis, and reversal of surgery-induced colonic VDR downregulation. Collectively, our findings demonstrate that paricalcitol ameliorates CPTP-associated cognitive dysfunction. These protective effects are associated with restored colonic VDR expression, suggesting a potential involvement of VDR signaling. This study provides a novel experimental basis for the potential clinical application of paricalcitol in preventing and treating pain-related cognitive dysfunction.